Clinical Circulating Tumor DNA Testing for Precision Oncology

Circulating tumor DNA testing is changing how clinicians and researchers study cancer at the molecular level. By analyzing tumor-derived DNA fragments in blood, this form of liquid biopsy can reveal genomic alterations without always requiring a new tissue sample.

Clinical ctDNA testing is increasingly used in precision oncology to support molecular profiling, targeted therapy selection, resistance detection, and clinical-trial enrollment. It also offers promising opportunities for treatment monitoring, molecular residual disease assessment, and recurrence surveillance. However, plasma testing has important limitations. A negative result may reflect low tumor shedding rather than the true absence of an alteration. For this reason, ctDNA analysis should usually complement tissue testing rather than replace it entirely.

What Is Circulating Tumor DNA?

Circulating tumor DNA, commonly abbreviated as ctDNA, consists of short DNA fragments released by cancer cells into the bloodstream.These fragments may carry tumor-associated molecular changes, including mutations, gene fusions, insertions, deletions, copy-number alterations, and methylation patterns.

ctDNA is part of a larger pool called cell-free DNA, or cfDNA. Most cfDNA may come from healthy blood and tissue cells, while only a small portion may originate from a tumor.The amount of detectable tumor DNA can vary according to cancer type, disease stage, tumor burden, metastatic location, treatment status, and biological shedding.

ctDNA Versus Cell-Free DNA

The terms ctDNA and cfDNA are related but should not be used interchangeably. Cell-free DNA includes all extracellular DNA fragments circulating in the blood. These fragments may come from normal cells, inflammatory processes, pregnancy, tissue injury, or cancer.

Circulating tumor DNA refers specifically to the tumor-derived fraction of cfDNA. This distinction is clinically important because a plasma sample may contain abundant cfDNA but very little ctDNA. When the tumor fraction is low, cancer-associated alterations may fall below the assay’s detection limit.

Why is ctDNA Important in Precision Oncology?

Precision oncology uses molecular information to help classify cancer and guide treatment decisions. Two patients with tumors in the same organ may have different driver mutations, resistance mechanisms, and treatment sensitivities. Clinical ctDNA testing can help identify these differences through a blood sample.

It may support:

• Detection of actionable genomic alterations
• Selection of targeted therapies
• Identification of resistance mutations
• Molecular profiling when tissue is unavailable
• Repeat testing during treatment
• Clinical-trial matching

The greatest clinical value currently lies in advanced or metastatic cancer, where plasma genomic testing may provide useful molecular information when tissue is limited, difficult to obtain, or no longer reflects the current tumor profile.

How Does Clinical ctDNA Testing Work?

A clinical ctDNA workflow includes several carefully controlled stages.

Blood Collection and Plasma Preparation

Blood is collected in a standard or stabilizing tube. Plasma is then separated from blood cells through controlled centrifugation. Processing time is important. If blood cells break down before plasma separation, they may release normal genomic DNA and dilute the tumor-derived signal.

Cell-Free DNA Extraction

Short DNA fragments are isolated from plasma using magnetic beads, silica-based systems, or automated extraction platforms. The extraction method must recover low-abundance DNA efficiently while limiting contamination and sample loss.

Molecular Detection

The isolated DNA may be analyzed using digital PCR, targeted next-generation sequencing, or other high-sensitivity methods. The selected technology depends on whether the goal is focused mutation detection, broad genomic profiling, treatment monitoring, or residual-disease analysis.

Bioinformatic Interpretation

Sequencing data are processed to remove technical noise, identify variants, calculate variant allele fractions, and classify clinically relevant findings. Results must then be interpreted according to tumor type, treatment history, current evidence, and the assay’s validated intended use.

Technologies Used for ctDNA Testing

Quantitative PCR

Quantitative PCR can detect selected DNA variants when the target is already known. It is fast, accessible, and cost-effective, but it has limited multiplexing and is less suitable for broad molecular profiling.

Digital PCR

Digital PCR divides a sample into thousands of small reactions, allowing rare mutant molecules to be detected against a large background of normal DNA.

It is particularly useful for:

• Known mutation detection
• Sensitive variant quantification
• Treatment-response monitoring
• Resistance tracking
• Molecular residual disease research

Its main limitation is that only a relatively small number of predefined targets can be analyzed at one time.

Targeted Next-Generation Sequencing

Targeted NGS panels examine multiple cancer-related genes or genomic regions in one workflow.

Depending on the assay, they may detect:

• Single-nucleotide variants
• Insertions and deletions
• Gene fusions
• Copy-number changes
• Selected genomic signatures

NGS is widely used for blood-based tumor profiling because it combines broad molecular coverage with deep sequencing. However, it requires complex analytical validation, bioinformatics, quality control, and careful interpretation.

Unique Molecular Identifiers

Unique molecular identifiers are short molecular tags added to original DNA fragments before amplification. They help distinguish true variants from PCR duplicates and sequencing errors, improving confidence in low-frequency mutation detection.

Duplex Sequencing

Duplex sequencing analyzes both complementary strands of a DNA molecule. A true mutation should appear at the corresponding position on both strands. This can reduce technical error, although it increases sequencing requirements and workflow complexity.

What Can ctDNA Testing Detect?

Clinical ctDNA assays may identify several classes of genomic alterations. Common targets include mutations in genes such as EGFR, KRAS, NRAS, BRAF, PIK3CA, ESR1, BRCA1, and BRCA2. Some assays can also detect gene rearrangements involving ALK, ROS1, RET, or NTRK, as well as copy-number changes affecting genes such as ERBB2/HER2 or MET. Broader tests may report microsatellite instability, blood-based tumor mutational burden, or tumor-fraction estimates. Not every test detects every alteration equally well. Gene coverage, variant classes, sequencing depth, and detection limits vary between platforms.

Clinical Applications of ctDNA Testing

Molecular Profiling in Advanced Cancer

The most established clinical application is molecular profiling in advanced or metastatic disease.

Plasma testing may be especially helpful when:

• Tissue is unavailable
• A biopsy would be risky
• The existing sample is insufficient
• A rapid molecular result is needed
• The tumor may have evolved after treatment

A detected actionable alteration may help guide targeted therapy or clinical-trial enrollment.

Targeted Therapy Selection

ctDNA can reveal biomarkers linked to approved or investigational targeted treatments. Examples may involve alterations in EGFR, BRAF, KRAS, PIK3CA, ESR1, BRCA1, BRCA2, MET, RET, or ERBB2. The treatment relationship must always be interpreted according to the specific cancer type, alteration, assay, and current therapeutic labeling. A biomarker that is actionable in one tumor type may not have the same clinical meaning in another.

Detecting Treatment Resistance

Cancer can evolve under treatment pressure.

Serial ctDNA testing may detect emerging resistance-associated alterations, including secondary mutations, pathway reactivation, or new tumor subclones. This can provide a broader view of tumor evolution than a single tissue sample collected earlier in the disease course.

Monitoring Treatment Response

Changes in ctDNA levels or variant allele fractions may provide information about molecular response. A decline may suggest reduced tumor burden, while persistent or increasing ctDNA may indicate residual disease or progression. However, ctDNA changes are not universally validated as substitutes for imaging, symptoms, or clinical outcomes. Interpretation depends on the tumor type, treatment, timing, and assay.

Molecular Residual Disease

Molecular residual disease refers to small amounts of tumor-associated material that remain after surgery or another potentially curative treatment. Tumor-informed assays may track mutations identified from a patient’s tissue and search for those variants in plasma. Post-treatment ctDNA positivity is often associated with a greater risk of recurrence. Researchers are studying whether this information can guide adjuvant treatment decisions. This application is promising, but clinical use is not equally established across all cancers.

Recurrence Surveillance

Repeated ctDNA testing may identify molecular recurrence before symptoms or radiographic findings appear. Earlier molecular detection could support closer monitoring or additional investigation. However, the key clinical question is whether acting on an earlier signal improves patient outcomes. Routine surveillance strategies, therefore, require disease-specific evidence.

Early Cancer Detection

ctDNA is also being studied for early and multi-cancer detection. Potential signals include mutations, methylation patterns, fragment characteristics, and tissue-of-origin signatures. This is one of the most challenging applications because early-stage tumors may release extremely small amounts of DNA. False-positive results, overdiagnosis, and uncertain follow-up pathways remain important concerns.

Tumor-Informed Versus Tumor-Naïve Testing

Tumor-Informed Testing

A tumor-informed assay begins by sequencing a patient’s tumor tissue. Selected tumor-specific variants are then tracked in plasma. This approach offers strong specificity and is especially relevant to molecular residual disease research. Its limitations include the need for tissue, additional development time, and the possibility that new tumor clones may not be represented in the original panel.

Tumor-Naïve Testing

A tumor-naïve test does not require prior tissue sequencing. It may use a fixed gene panel, methylation signature, fragmentomic pattern, or another predefined model. This approach is faster and more scalable, but background variants and low tumor fractions can make interpretation more difficult.

ctDNA Testing Versus Tissue Biopsy

Tissue testing remains essential for histological diagnosis and often provides a stronger tumor signal.

How Should ctDNA Results Be Interpreted?

Positive Result

A positive finding may support targeted treatment when the alteration is clinically actionable, the cancer type matches the evidence, and the test is validated for the relevant purpose. Not every reported variant has an approved treatment.

Negative Result

A negative result does not always mean that the tumor lacks the alteration.

It may indicate:

• Low tumor shedding
• Insufficient tumor fraction
• A variant below the detection limit
• Incomplete panel coverage
• An uninformative sample

Tissue testing may still be appropriate after a noninformative plasma result.

Low Variant Allele Fraction

A low-frequency finding may represent a small tumor subclone, low disease burden, technical noise, clonal hematopoiesis, or a true emerging resistance mechanism. Clinical context and assay quality are essential for interpretation.

Clonal Hematopoiesis and Other Sources of Error

Clonal hematopoiesis occurs when blood-forming stem cells acquire mutations and produce expanded cell populations. These mutations can appear in plasma cfDNA even though they do not originate from a solid tumor. Commonly affected genes include DNMT3A, TET2, ASXL1, TP53, and JAK2.

Matched white-blood-cell sequencing, variant-pattern review, and clinical correlation can help distinguish hematopoietic variants from tumor-derived changes. Other possible sources of error include sequencing artifacts, germline variants, poor sample processing, low DNA recovery, and incorrect variant interpretation.

FDA-Approved Plasma Companion Diagnostics

Some plasma-based tests have received FDA approval as companion diagnostics for specific biomarker–therapy relationships. A commercial assay may analyze many genes, but its approved companion diagnostic claims may apply only to selected alterations, treatments, and tumor types.

This distinction is important. A broad genomic report is not automatically the same as an FDA-approved treatment claim. Because regulatory indications change over time, clinicians and researchers should consult current official resources rather than rely on a static list.

What Makes a Reliable ctDNA Assay?

A clinically reliable test should demonstrate:

• Strong analytical sensitivity
• High specificity
• Accurate variant detection
• Reproducibility
• Validated detection limits
• Appropriate gene and variant coverage
• Stable sample processing
• Robust bioinformatic filtering
• Clear reporting rules

The assay must also be fit for its intended purpose. A panel designed for advanced cancer profiling may not be sensitive enough for postoperative residual disease testing. Similarly, a highly focused MRD assay may not provide broad treatment-selection information.

Advantages of Clinical ctDNA Testing

Clinical ctDNA testing offers several important advantages. It is minimally invasive, easier to repeat, and may provide molecular information when tissue is limited. It can also reveal resistance-associated changes and potentially capture alterations released from more than one tumor location. In precision oncology, these strengths create positive opportunities for faster profiling, more informed treatment selection, and improved longitudinal monitoring.

Limitations of CTDNA Testing

The main limitation is low tumor fraction. Some cancers release very little DNA into circulation, especially at an early stage or when disease burden is low.

Other challenges include:

• Variable tumor shedding
• Clonal hematopoiesis
• Germline findings
• Preanalytical variation
• Platform differences
• Limited sensitivity for some fusions and copy-number changes
• False-positive and false-negative results
• Uneven clinical utility across applications

Analytical sensitivity alone does not prove that using a test will improve clinical outcomes.

Research Support for Precision Oncology

Clinical ctDNA testing relies mainly on validated molecular platforms, but broader translational research also requires high-quality proteins, antibodies, enzymes, and cancer-associated targets. Beta LifeScience provides recombinant cancer proteins, antibodies, DNA-modifying enzymes, immune-checkpoint proteins, and custom protein services that may support biomarker discovery, target validation, and translational oncology research. These research-use products should remain clearly distinguished from regulated clinical sequencing tests or approved companion diagnostics.

Future Directions

The future of ctDNA testing is moving toward greater sensitivity, broader biological coverage, and more integrated interpretation.

Emerging areas include:

• Tumor-informed residual-disease testing
• Methylation analysis
• Fragmentomics
• Multi-omics liquid biopsy
• Improved fusion detection
• Machine-learning classifiers
• Longitudinal molecular monitoring
• Integration with imaging and clinical data

The most valuable advances will be those that not only detect smaller amounts of disease but also demonstrate that acting on the result improves patient outcomes.

FAQs

What is circulating tumor DNA?

Circulating tumor DNA consists of tumor-derived DNA fragments found in the bloodstream. These fragments may carry cancer-associated genomic alterations.

What is the difference between ctDNA and cfDNA?

cfDNA includes DNA released from normal and abnormal cells. ctDNA is the tumor-derived portion of total cell-free DNA.

Can ctDNA testing guide targeted therapy?

Yes. It may identify actionable alterations linked to targeted treatments, provided the result is clinically validated for the relevant cancer type and treatment.

Can ctDNA replace a tissue biopsy?

Not completely. Tissue is still required for histological diagnosis and may be needed after a negative or noninformative plasma result.

What does a negative ctDNA result mean?

It may mean the alteration is absent, but it can also reflect low tumor shedding, insufficient tumor fraction, or limited assay coverage.

What is tumor-informed ctDNA testing?

Tumor-informed testing uses variants identified from a patient’s tissue to create a personalized plasma-monitoring assay.

What is clonal hematopoiesis?

Clonal hematopoiesis is the expansion of blood-cell clones carrying acquired mutations. These variants may appear in plasma and be mistaken for tumor-derived changes.

Is ctDNA testing FDA-approved?

Some plasma assays have FDA-approved companion diagnostic claims for specific biomarkers, treatments, and cancer indications. Approval does not automatically apply to every result reported by the test.

Conclusion

Clinical circulating tumor DNA testing has become an important tool in precision oncology. It can support blood-based molecular profiling, targeted therapy selection, resistance detection, and repeat assessment of tumor evolution. Its strengths include minimally invasive sampling, faster access to molecular information, and easier longitudinal testing. Its limitations include low tumor shedding, clonal hematopoiesis, platform variability, and the possibility of false-negative results.

The most responsible use of ctDNA testing combines validated assays, careful interpretation, current treatment evidence, and tissue analysis when needed. As technology and clinical evidence continue to improve, plasma genomic testing can contribute to more precise and informed cancer care.